Top

Neurocritical Care

Published in:

01-08-2009 | Original Article

IV vs. IA TPA in Acute Ischemic Stroke with CT Angiographic Evidence of Major Vessel Occlusion: A Feasibility Study

Authors: Souvik Sen, David Y. Huang, Omid Akhavan, Susan Wilson, Piero Verro, Sten Solander

Published in: Neurocritical Care | Issue 1/2009

Abstract

Background and Aims

Studies suggest that stroke patients with thrombus in a major cerebral vessel respond less favorably to intravenous (IV) thrombolysis. The purpose of this study was to test the feasibility of a protocol comparing IV versus intra-arterial (IA) recombinant tissue plasminogen activator (TPA) in an acute ischemic stroke with major vessel occlusion.

Methods

Consecutive ischemic stroke patients presenting <3 h from symptom onset with major vessel occlusion on CT angiogram (CTA) were randomly assigned to IV TPA (per NINDS protocol) or IA TPA (22 mg over 2 h). Demographics, times to presentation and thrombolysis, presenting NIH stroke scale (NIHSS) and 90-day NIHSS, Barthel Index, and modified Rankin Scale were recorded. CT-scans at 24-h were reviewed for presence of hemorrhage. Recanalization was determined by post-procedure MR angiograms, which are obtained the day after thrombolytic therapy.

Results

Seven patients (median NIHSS = 16) were randomized to IV (N = 4) or IA (N = 3) TPA. There were no significant differences in the presentation NIHSS, time to presentation, or time to treatment between the two groups. Hemorrhage was noted in one patient in the IA group (asymptomatic) and one patient in the IV group (symptomatic). Recanalization was seen in all patients treated with IA TPA and none treated with IV TPA (P = 0.03, Fisher’s Exact test).

Conclusions

We found that it is feasible to conduct a trial comparing IV vs. IA TPA in ischemic stroke patients with major vessel occlusion presenting <3 h from onset. Patients treated with IA TPA showed a trend toward higher rate of recanalization. A larger trial may be designed to test safety and effectiveness of IA TPA in this specific group of stroke patients.

NINDS Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7. doi:10.1056/NEJM199512143332401.CrossRef

Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29. doi:10.1056/NEJMoa0804656.PubMedCrossRef

Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA. 1999;282(21):2003–11. doi:10.1001/jama.282.21.2003.PubMedCrossRef

Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke. Stroke. 2007;38(5):1655–711. doi:10.1161/STROKEAHA.107.181486.PubMedCrossRef

Lisboa RC, Jovanovic BD, Alberts MJ. Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. Stroke. 2002;33(12):2866–71. doi:10.1161/01.STR.0000038987.62325.14.PubMedCrossRef

Lev MH, Farkas J, Rodriguez VR, Schwamm LH, Hunter GJ, Putman CM, et al. CT angiography in the rapid triage of patients with hyperacute stroke to intraarterial thrombolysis: accuracy in the detection of large vessel thrombus. J Comput Assist Tomogr. 2001;25(4):520–8. doi:10.1097/00004728-200107000-00003.PubMedCrossRef

IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004;35(4):904–11. doi:10.1161/01.STR.0000121641.77121.98.CrossRef

Ciccone A, Valvassori L, Gasparotti R, Scomazzoni F, Ballabio E, Sterzi R. Debunking 7 myths that hamper the realization of randomized controlled trials on intra-arterial thrombolysis for acute ischemic stroke. Stroke. 2007;38(7):2191–5. doi:10.1161/STROKEAHA.106.465567.PubMedCrossRef

Bookstein JJ, Bookstein FL. Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude. J Vasc Interv Radiol. 2000;11:299–303. doi:10.1016/S1051-0443(07)61421-3.PubMedCrossRef

10.

TIMI Study Group The Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I findings. N Engl J Med. 1985;312:932–6.

11.

Neumann-Haefelin T, de Rochemont R, Fiebach JB, Gass A, Nolte C, Kucinski T, et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke. 2004;35:109–14. doi:10.1161/01.STR.0000106482.31425.D1.PubMedCrossRef

12.

Bastianello S, Pierallini A, Colonnese C, Brughitta G, Angeloni U, Antonelli M, et al. Fieschi, Bozzao L. Hyperdense middle cerebral artery CT sign. Neuroradiology. 1991;33:207–11. doi:10.1007/BF00588219.PubMedCrossRef

13.

Moulin T, Cattin F, Crépin-Leblond T, Tatu L, Chavot D, Piotin M, et al. Early CT signs in acute middle cerebral artery infarction: predictive value for subsequent infarct locations and outcome. Neurology. 1996;47:366–75.PubMed

14.

Zorzon M, Mase G, Pozzi-Mucelli F, Biasutti E, Antonutti L, Iona L, et al. Increased density in the middle cerebral artery by nonenhanced computed tomography: prognostic value in acute cerebral infarction. Eur Neurol. 1993;33:256–9. doi:10.1159/000116949.PubMedCrossRef

15.

Launes J, Ketonen L. Dense middle cerebral artery sign: an indicator of poor outcome in middle cerebral artery area infarction. J Neurol Neurosurg Psychiatry. 1987;50:1550–2. doi:10.1136/jnnp.50.11.1550.PubMedCrossRef

16.

Manelfe C, Larrue V, von Kummer R, Bozzao L, Ringleb P, Bastianello S, et al. Association of hyperdense middle cerebral artery sign with clinical outcome in patients with tissue plasminogen activator. Stroke. 1999;30:769–72.PubMed

17.

Tomsick T, Brott T, Barsan W, Broderick J, Clarke Haley E, Spilker J, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol. 1996;17:79–85.PubMed

18.

The NINDS rtPA Stroke Study Group. Generalized efficacy of rtPA for acute stroke: subgroup analysis of the NINDS rtPA stroke trial. Stroke. 1997;28:2119–25.

19.

Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet. 2004;363:804–13. doi:10.1016/S0140-6736(04)15697-3.PubMedCrossRef

20.

Agarwal P, Kumar S, Hariharan S, Eshkar N, Verro P, Cohen B, et al. Hyperdense middle cerebral artery sign: can it be used to select intraarterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis. 2004;17:182–90. doi:10.1159/000075789.PubMedCrossRef

21.

Garg N, Eshkar N, Tanenbaum L, Cohen B, Sen S. Computed tomography angiographic correlates of early computed tomography signs in acute ischemic stroke. J Neuroimaging. 2004;14(3):242–5. doi:10.1177/1051228404264938.PubMedCrossRef

22.

http://clinicaltrials.gov/ct2/show/NCT00640367?term=synthesis&rank=10. Accessed December 27, 2008.

23.

http://www.neurorad-bern.ch/combatstroke/. Accessed December 27, 2008.

24.

Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis. 2005;20(1):12–7. doi:10.1159/000086121.PubMedCrossRef

25.

Broderick JP. Practical considerations in the early treatment of ischemic stroke. Am Fam Physician. 1998;57:73–9.PubMed

26.

Mattle HP, Arnold M, Georgiadis D, Baumann C, Nedeltchev K, Benninger D, et al. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke. 2008;39(2):379–83. doi:10.1161/STROKEAHA.107.492348.PubMedCrossRef

27.

Rha JH, Saver JL. The impact of recanalization on ischemic stroke ourcome, a meta-analysis. Stroke. 2007;38:967–73. doi:10.1161/01.STR.0000258112.14918.24.PubMedCrossRef

Title: IV vs. IA TPA in Acute Ischemic Stroke with CT Angiographic Evidence of Major Vessel Occlusion: A Feasibility Study
Authors: Souvik Sen
David Y. Huang
Omid Akhavan
Susan Wilson
Piero Verro
Sten Solander
Publication date: 01-08-2009
Publisher: Humana Press Inc
Published in: Neurocritical Care / Issue 1/2009
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI: https://doi.org/10.1007/s12028-009-9204-1

2024 ASCO Annual Meeting

Springer Medicine

IV vs. IA TPA in Acute Ischemic Stroke with CT Angiographic Evidence of Major Vessel Occlusion: A Feasibility Study

Abstract

Background and Aims

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background and Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Continuous Renal Replacement Therapy for Refractory Intracranial Hypertension

How Patients Die After Intracerebral Hemorrhage

Methylene Blue-Associated Serotonin Syndrome: A ‘Green’ Encephalopathy After Parathyroidectomy

Safety and Efficacy of Levetiracetam for Critically Ill Patients with Seizures

Role of Vasopressor Administration in Patients with Acute Neurologic Injury

Non-Peptide Arginine-Vasopressin Antagonists (Vaptans) for the Treatment of Hyponatremia in Neurocritical Care: A New Alternative?